WATERTOWN, Mass. -- (BUSINESS WIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against drug-resistant bacteria, today announced presentations at two upcoming investor conferences. The Company's lead antibiotic candidate, eravacycline, is currently in Phase 3 development to treat multidrug-resistant (MDR) infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the 21st Annual Future Leaders in the Biotech Industry Conference on Friday, March 28 at 1:30 p.m. Eastern Time. The conference will take place at the Millennium Broadway Hotel in New York City.
Mr. Macdonald will also be presenting at the 13th Annual Needham Life Sciences Conference on Wednesday, April 9 at 11:20 a.m. Eastern Time. The conference will take place at the Westin Grand Central in New York City. A live audio webcast of the presentation will be available on the Company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 90 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic. The safety and efficacy of eravacycline is currently being studied in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). Two Phase 3 clinical trials are ongoing: IGNITE 1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE 2 for complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability.